Phase 4 N=30 Is Levocetirizine Less Sedating Than Cetirizine?
Allergic Rhinitis
Primary: Modified Epworth Sleepiness Scale — 6.14; 6.69; 7.48 units on a scale — p=.27
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
Rheumatoid Arthritis
Primary: Mean Injection Site Pain on a Visual Analogue Scale (VAS) — 3.3; 1.6 cm
N/A N=61,864 Risk of Cancer Among Pantoprazole Users
Esophagitis
Primary: Incidence Rate of Gastric Cancer — 19.88; 23.73 incidence per 100000 person-years
N/A N=63 Abbott ESA Chagas Assay Post-Market Study
Chagas Disease
Primary: ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas — 92.06 percent agreement to RIPA
Phase 2 N=65 Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Primary: Number of Participants Who Achieved a Complete Response — 47 Participants
Phase 2 N=546 Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia · Acute Myeloid Leukemia With Myelodysplasia-Related Changes · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Number of Participants Who Completed Maintenance Decitabine. — 62 participants
Phase 2 N=61 A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
Rheumatoid Arthritis
Primary: Mean Injection Site Pain on a Visual Analogue Scale (VAS) — 4.2; 0.9 cm
Phase 2 N=30 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Childhood High-grade Cerebellar Astrocytoma · Childhood High-grade Cerebral Astrocytoma · Recurrent Childhood Anaplastic Astrocytoma
Primary: Objective Response to Cilengitide — 1; 23 participants
N/A N=50 Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Change From Baseline in Intact Parathyroid Hormone at 6 Months — -6.2 pmol/L
Phase 2 N=64 Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
Hepatitis C
Primary: Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period — 87.5; 83.3; 86.7; 85.7 percentage of participants
Phase 2 N=46 Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Oral Chronic Graft-versus-host Disease
Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants
Phase 1 N=66 Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Impaired Renal Function
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 445892.7; 932688.3; 1531185.8; 1261081.6 ng*hr/ml
Phase 4 N=351 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion — 6.5 percentage of participants
Phase 2 N=147 Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
Hepatitis C Virus
Primary: Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period — 97.9; 97.9; 100.0; 96.0 percentage of participants
Phase 3 N=301 Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy
Renal Failure
Primary: Contrast-induced Nephropathy — 6.1; 6.0 percentage of contrast nephropaty